Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Sherlock Biosciences

Main focus: Development of novel Cas-enzymes for diagnostics

Company stage: Commercial (diagnostics), pre-clinical (therapeutics)

Diseases: COVID-19 (diagnostics)

Genome editing tool: CRISPR-Cas12a, CRISPR-Cas12b, CRISPR-Cas13.

Funding stage: Private

Location: Cambridge, MA, USA

Website: https://sherlock.bio/

Partners: Tolo Biotech

Sherlock Biosciences is a CRISPR diagnostics company. The company deploys its SHERLOCK™- and INSPECTR™-platforms that are based on novel Cas-enzymes, and so far, it has commercialised a novel CRISPR-based SARS-CoV-2 detection kit. The company is co-founded by Feng Zhang, who also co-founded Arbor Biotechnologies and Beam Therapeutics.

Sherlock Biosciences, Inc.

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

CMN Weekly (22 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 22, 2024

Some of the best links we picked up around the internet

Tune Therapeutics to Initiate Clinical Trial of...

CMN Clinical

Nov. 21, 2024

Tune Therapeutics has received clinical trial application approval from the New Zealand Medicines and Medical Devices Safety Authority to initiate a...

CRISPR Unlocks Sweeter Tomatoes Without Yield Loss

Carbon

Nov. 19, 2024

Chinese scientists have achieved a significant advance in tomato agriculture by leveraging CRISPR–Cas9 to enhance sweetness without yield loss. The...

Tackling Antibiotic-Resistant Staphylococcus...

CMN Interview

Nov. 18, 2024

Researchers in Japan have used phagemids for the delivery of CRISPR components to bacteriophage, selectively killing multi-drug resistant bacteria in...

CMN Weekly (15 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 15, 2024

Some of the best links we picked up around the internet

CRISPR Screens Identify Vital lncRNAs

CMN Briefs

Nov. 12, 2024

American researchers have used transcriptome-wide CRISPR-Cas13 screens in multiple human cell lines to identify 46 universally essential and more than...